Using metformin low risk in patients with renal disease

A study of more than 50,000 Swedish patients with type 2 diabetes who had different levels of renal impairment found no increased risk of cardiovascular disease, all-cause mortality or acidosis/serious infection with metformin.

Metformin also showed a lower risk for CVD and all-cause mortality than insulin and a slightly lower risk for all-cause mortality compared with other oral hypoglycaemic agents over the four years of follow-up.

The results prompted the authors to state that “the benefits of metformin use in clinical practice clearly outbalance the